SEARCH

SEARCH BY CITATION

References

  • 1
    Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434438.
  • 2
    Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 12211231.
  • 3
    Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 16491657.
  • 4
    Ruhl C, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the U.S. Gastroenterology 2003; 124: 7179.
  • 5
    Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, et al. Prevalence of and risk factors for hepatic steatosis in northern Italy. Ann Intern Med 2000; 132: 112117.
  • 6
    Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988; 27: 142149.
  • 7
    Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. HEPATOLOGY 1990; 30: 13561362.
  • 8
    Matteoni CA, Younossi SM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 14131419.
  • 9
    Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carrucci P, Musso A, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134140.
  • 10
    Charlton M, Kasparova P, Weston S, Lindor K, Maor-Kendler Y, Wiesner RH, Rosen CB, et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001; 7: 608614.
  • 11
    Angulo P, Lindor KD. Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin Liver Dis 2001; 21: 8188.
  • 12
    Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358; 893894.
  • 13
    Caldwell SH, Hespenheide EE, Redlick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 519525.
    Direct Link:
  • 14
    Neuschwander-Tetri BA, Brunt EM, Bacon BR, Sponseller C, Wehmeier KR. Histological improvement in NASH following reduction in insulin resistance with 48-week treatment with PPARγ agonist rosiglitazone [abstract]. HEPATOLOGY 2002; 36: 379A.
  • 15
    Abdelmalek M, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001; 96: 27112717.
    Direct Link:
  • 16
    Hasegawa T, Yoneda M, Makamura K, Makino I, Terano A. Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001; 15: 16671672.
  • 17
    Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid “mechanisms of action and clinical use in hepatobiliary disorders”. J Hepatol 2001; 35: 134146.
  • 18
    Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, et al. Ursodeoxycholic acid or clofibrate in the treatment on non-alcoholic-induced steatohepatitis: a pilot study. HEPATOLOGY 1996; 23: 14641467.
  • 19
    Brunt EM, Janney G, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 24672474.
    Direct Link:
  • 20
    Kobak GE, Deutsch G, Dahl R, Devereaux MW, Gumpricht E, Sokol RJ. Fat-laden hepatocytes are more prone to cellular necrosis than apoptosis when exposed to hydrophobic bile acids. Gastroenterology 2002; 122: A642.
  • 21
    Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE, et al. Reversal of obesity and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001; 293: 16731677.
  • 22
    Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389: 610614.
  • 23
    Neuman M, Angulo P, Malkiewicz I, Jorgensen R, Shear N, Dickson ER, Haber J, et al. Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. J Gastroenterol Hepatol 2002; 17: 196202.
  • 24
    Angulo P, Dickson ER, Therneau TM, Jorgensen RA, Smith C, DeSotel CK, Lange SM, et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 1999; 30: 830835.
  • 25
    Harnois D, Angulo P, Jorgensen RA, LaRusso NF, Lindor KD. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001; 96: 15581562.
    Direct Link:
  • 26
    Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001; 121: 900907.
  • 27
    Colombo C, Crosignani A, Assaisso M, Battezzati PM, Podda M, Giunta A, Zimmer-Nechemias L, et al. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: A dose-response study. HEPATOLOGY 1992; 16: 924930.
  • 28
    Abdelmalek M, Ludwig J, Lindor KD. Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol 1995; 20: 127130.